Search clinical trials for: CASIRIVIMAB IMDEVIMAB

Total 26 results

Regeneron Pharmaceuticals

Completed

COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers

Healthy | Chronic Stable Illness

United States
University of Ulm

Completed

Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application (CasiTocCOVID)

COVID-19 | Critically Ill | Outcome, Fatal | Interleukin 6 | Tocilizumab

Germany
Regeneron Pharmaceuticals

No longer available

Compassionate Use of REGN-COV2 for the Treatment of COVID-19

COVID-19
Regeneron Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

COVID-19

United States, Mexico, Romania
Regeneron Pharmaceuticals

Terminated

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

SARS-CoV-2

United States
Regeneron Pharmaceuticals

Terminated

A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

Immunocompromised

United States, Mexico
Academisch Medisch Centrum - Universiteit van Amsterdam...

Recruiting

TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2 (TURN-COVID)

COVID-19

Netherlands
Erin McCreary
University of Pittsburgh

Terminated

UPMC OPTIMISE-C19 Trial, a COVID-19 Study (OPTIMISE-C19)

Covid19

United States
Regeneron Pharmaceuticals

Completed

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

Healthy Participants

United States, Moldova, Republic of, Romania
Regeneron Pharmaceuticals

Completed

COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection

COVID-19

United States
Regeneron Pharmaceuticals

Terminated

COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

COVID-19

United States
Regeneron Pharmaceuticals

Completed

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

COVID-19

United States, Mexico, Romania, Brazil, Chile, Moldova, Republic of
Sohail Rao

Recruiting

Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

Covid19

United States
Regeneron Pharmaceuticals

Terminated

COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19

COVID-19

United States
Mansoura University Hospital

Completed

Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients

COVID-19

Egypt
Regeneron Pharmaceuticals

Completed

Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19

Healthy | Chronic Stable Illness

United States
Regeneron Pharmaceuticals

Completed

COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers

Healthy | Chronic Stable Illness

United States
Northwell Health
Regeneron Pharmaceuticals

Withdrawn

Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody Cocktail

COVID-19 | Organ Transplant

United States
Azienda Ospedaliera Universitaria Integrata Verona
Agenzia Italiana del Farmaco; Azienda Sanitaria-Universitaria Integrata di...

Terminated

Non-inferiority Trial on Monoclonal Antibodies in COVID-19 (MANTICO)

COVID-19

Italy
University of Milano Bicocca

Recruiting

COVID-19 and Disease Progression to the Severe Form: A Study on the Use of Monoclonal Antibodies Against SARS-CoV-2 (CONDIVIDIAMO)

COVID-19

Italy
University of Calgary
Sunnybrook Research Institute

Terminated

Treatment of Nosocomial COVID-19 (CATCO-NOS)

Covid19 | SARS-CoV2 Infection | Nosocomial Infection

Canada
Pregistry

Recruiting

COVID-19 International Drug Pregnancy Registry (COVID-PR)

Covid19

United States
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AIDS Clinical Trials... and other collaborators

Completed

ACTIV-2: A Study for Outpatients With COVID-19

Covid19 | Coronavirus

United States, Argentina, Brazil, Guatemala, Mexico, Philippines, Puerto Rico, South Africa, Canada
University of Oxford
Bill and Melinda Gates Foundation; Department for International Development... and other collaborators

Recruiting

Randomised Evaluation of COVID-19 Therapy (RECOVERY)

Severe Acute Respiratory Syndrome

Ghana, Indonesia, Nepal, South Africa, United Kingdom, Vietnam, India
Assiut University

Not yet recruiting

NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major

Thalassemia Major
Sohag University

Completed

Evaluation of Lacrimal Punctal Changes by Anterior Segment Optical Coherence Tomography AS-OCT After Topical Combined Antibiotics and Steroids Treatment in Cases of Inflammatory Punctual Stenosis

Ophthalmopathy , Lacrimal System

Egypt

3

Subscribe